Skip to main content

Posts

Trap Purchases and Manufactured Jurisdiction in Indian IP Litigation

  Trap Purchases and Manufactured Jurisdiction in Indian IP Litigation A study of SML Ltd. v. M/s Happy Agro Chemicals and the doctrine of trap transactions Introduction In intellectual property disputes, few procedural issues matter as much as deciding where a case can be filed. The choice of court often shapes the entire journey of the case — from how quickly interim orders are granted, to the attitude of the local lawyers, to the practical burden placed on a defendant who must fight far from home. Because the forum is so important, plaintiffs sometimes try to influence it. The most common method is the trap purchase : a test buy arranged by the plaintiff, where an investigator pretends to be a regular customer, purchases the allegedly infringing product, and keeps the invoice and packaging. Later, this evidence is used not only to show infringement but — more controversially — to argue that the cause of action arose within the territory of the chosen court. Tra...
Recent posts

Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents

  Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...

Case Analysis Intra‑Cellular Therapies, Inc. v. Controller of Patents (Delhi High Court, 2026)

  I. Overview and Procedural Posture The Delhi High Court, in an appeal under Section 117A of the Patents Act, 1970, upheld the Controller's rejection (order dated 27.04.2023) of the patent application (No. 201817033732) titled "Organic Compounds" and covering deuterated heterocycle-fused gamma-carboline compounds (Formulas I–IV). The claims fell into two clusters: Claims 1–3 & 5–10 (Formula I–III compounds) and Claims 4 & 5–7 (Formula IV compounds), with Claim 11 as a dependent pharmaceutical composition claim. The claimed invention was for the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signalling systems and also has application in the treatment of diseases/disorders like anxiety, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, etc. The rejection rested on lack of novelty (Section 2(1)(j)), obviousness (Section 2(1)(ja)), and non-patentability under Sect...